CA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


CA Cancer J Clin 1997; 47:52
doi: 10.3322/canjclin.47.1.52
© 1997 American Cancer Society
This Article
Right arrow Full Text (PDF) Freely available
Right arrow Submit a letter to the editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fisher, E. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fisher, E. R.

CA: A Cancer Journal for Clinicians, Vol 47, Issue 1 52-64, Copyright © 1997 by American Cancer Society


ARTICLES

Pathobiological considerations relating to the treatment of intraductal carcinoma (ductal carcinoma in situ) of the breast

E. R. Fisher
National Surgical Adjuvant Breast and Bowel Project, Shadyside Hospital, Pittsburgh, Pennsylvania, USA.

Management of ductal carcinoma in situ has become one of the most controversial topics in breast disease. While mastectomy has been the traditional treatment, many now feel it is excessive in most cases. As a result, a great effort has been made to identify pathobiological characteristics of DCIS that can be used to stratify appropriate treatment decisions. This article reviews efforts to relate pathobiological characteristics to disease management and provides treatment recommendations based on the latest evidence.


This article has been cited by other articles:


Home page
JNCI J Natl Cancer InstHome page
E. R. Fisher and B. Fisher
Relation of a Recurrent Intraductal Carcinoma (Ductal Carcinoma In Situ) to the Primary Tumor
J Natl Cancer Inst, February 16, 2000; 92(4): 288 - 289.
[Full Text] [PDF]


Home page
Cancer Res.Home page
B. S. Reddy, T. Kawamori, R. A. Lubet, V. E. Steele, G. J. Kelloff, and C. V. Rao
Chemopreventive Efficacy of Sulindac Sulfone against Colon Cancer Depends on Time of Administration during Carcinogenic Process
Cancer Res., July 1, 1999; 59(14): 3387 - 3391.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by American Cancer Society.